<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Infections Archives &#8211; DHbriefs</title>
	<atom:link href="https://dhbriefs.com/cat_disease/infections/feed/" rel="self" type="application/rss+xml" />
	<link>https://dhbriefs.com/cat_disease/infections/</link>
	<description>All about the European digital health ecosystem</description>
	<lastBuildDate>Fri, 11 Aug 2023 07:51:41 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.5</generator>
	<item>
		<title>Bactolife</title>
		<link>https://dhbriefs.com/dbentry/bactolife/</link>
		
		<dc:creator><![CDATA[Dusan Belic]]></dc:creator>
		<pubDate>Fri, 11 Aug 2023 07:48:46 +0000</pubDate>
				<category><![CDATA[Europe]]></category>
		<guid isPermaLink="false">https://dhbriefs.com/?post_type=dbentry&#038;p=9891</guid>

					<description><![CDATA[<p>Bactolife uses its proprietary Binding Protein technology to develop novel biological solutions, strengthening the gut microbiome and helping solve the daunting challenge of antimicrobial resistance (AMR) development, as well as the general burden of infectious diseases. Its proprietary platform consists of a technology for selecting and producing Binding Proteins that acts on toxins without targeting ...</p>
<p>The post <a href="https://dhbriefs.com/dbentry/bactolife/">Bactolife</a> appeared first on <a href="https://dhbriefs.com">DHbriefs</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Bactolife uses its proprietary Binding Protein technology to develop novel biological solutions, strengthening the gut microbiome and helping solve the daunting challenge of antimicrobial resistance (AMR) development, as well as the general burden of infectious diseases. Its proprietary platform consists of a technology for selecting and producing Binding Proteins that acts on toxins without targeting growth or killing the bacteria directly. The company is developing and will market ingredients for Mothers &amp; Children, Elderly, Immunodeficient, Travelers &amp; Deployed and Animal Health. The company has proof of concept (PoC) of its technology among others from testing its most advanced animal health product, Ablacto+ that stabilizes the gut of piglets and reduce the severity of post weaning diarrhea (PWD), in more than 6,000 piglets.</p>
<p>The post <a href="https://dhbriefs.com/dbentry/bactolife/">Bactolife</a> appeared first on <a href="https://dhbriefs.com">DHbriefs</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Solu</title>
		<link>https://dhbriefs.com/dbentry/solu/</link>
		
		<dc:creator><![CDATA[Dusan Belic]]></dc:creator>
		<pubDate>Wed, 28 Jun 2023 06:56:43 +0000</pubDate>
				<category><![CDATA[Europe]]></category>
		<guid isPermaLink="false">https://dhbriefs.com/?post_type=dbentry&#038;p=9643</guid>

					<description><![CDATA[<p>Solu is building a bacterial DNA database, enabling the analysis, monitoring, and control of antibiotic-resistant bacteria. Its software makes it easier to understand, detect, and prevent the spread of antibiotic resistance and enables the development of new treatment methods against resistant bacteria. The company is collaborating with top international universities, including Stanford University and the ...</p>
<p>The post <a href="https://dhbriefs.com/dbentry/solu/">Solu</a> appeared first on <a href="https://dhbriefs.com">DHbriefs</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Solu is building a bacterial DNA database, enabling the analysis, monitoring, and control of antibiotic-resistant bacteria. Its software makes it easier to understand, detect, and prevent the spread of antibiotic resistance and enables the development of new treatment methods against resistant bacteria. The company is collaborating with top international universities, including Stanford University and the University of Hamburg, which use Solu&#8217;s product in their research on antibiotic resistance. In the future, Solu aims to build a pathogen DNA library to collect all pathogen data in real-time and can also model their evolution and identify new health-threatening pathogens more effectively.</p>
<p>The post <a href="https://dhbriefs.com/dbentry/solu/">Solu</a> appeared first on <a href="https://dhbriefs.com">DHbriefs</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>

<!--
Performance optimized by W3 Total Cache. Learn more: https://www.boldgrid.com/w3-total-cache/?utm_source=w3tc&utm_medium=footer_comment&utm_campaign=free_plugin

Page Caching using Disk: Enhanced 

Served from: dhbriefs.com @ 2026-06-29 02:30:13 by W3 Total Cache
-->